(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide
- Product Name
- (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide
- CAS No.
- 1196541-47-5
- Chemical Name
- (R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide
- Synonyms
- RG744;RG-7741;ARRY-575;EOS-61380;ARRY-575, RG7741;GDC0575 ARRY-575;GDC-0575, 10 mM in DMSO;GDC0575 (ARRY-575,RG7441);GDC-0575 (ARRY-575) ，S8526;GDC-0575 (ARRY-575, RG7741)
- CBNumber
- CB83142374
- Molecular Formula
- C16H20BrN5O
- Formula Weight
- 378.27
- MOL File
- 1196541-47-5.mol
(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide Property
- Density
- 1.619±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMF:30.0(Max Conc. mg/mL);79.31(Max Conc. mM)
DMSO:68.33(Max Conc. mg/mL);180.65(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.42(Max Conc. mM)
Ethanol:3.0(Max Conc. mg/mL);7.93(Max Conc. mM) - form
- A solid
- pka
- 14.25±0.40(Predicted)
- color
- Light yellow to yellow
- InChI
- InChI=1S/C16H20BrN5O/c17-11-6-19-15-13(14(11)22-5-1-2-10(18)8-22)12(7-20-15)21-16(23)9-3-4-9/h6-7,9-10H,1-5,8,18H2,(H,19,20)(H,21,23)/t10-/m1/s1
- InChIKey
- BAZRWWGASYWYGB-SNVBAGLBSA-N
- SMILES
- C1(C(NC2C3=C(N4CCC[C@@H](N)C4)C(Br)=CN=C3NC=2)=O)CC1
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H315Causes skin irritation
H317May cause an allergic skin reaction
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P271Use only outdoors or in a well-ventilated area.
P272Contaminated work clothing should not be allowed out of the workplace.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P312Call a POISON CENTER or doctor/physician if you feel unwell.
P321Specific treatment (see … on this label).
P333+P313IF SKIN irritation or rash occurs: Get medical advice/attention.
P337+P313IF eye irritation persists: Get medical advice/attention.
P363Wash contaminated clothing before reuse.
P403+P233Store in a well-ventilated place. Keep container tightly closed.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- CS-0043591
- Product name
- GDC-0575
- Purity
- 99.50%
- Packaging
- 5mg
- Price
- $210
- Updated
- 2021/12/16
- Product number
- CS-0043591
- Product name
- GDC-0575
- Purity
- 99.50%
- Packaging
- 10mg
- Price
- $360
- Updated
- 2021/12/16
- Product number
- CS-0043591
- Product name
- GDC-0575
- Purity
- 99.50%
- Packaging
- 25mg
- Price
- $720
- Updated
- 2021/12/16
- Product number
- CS-0043591
- Product name
- GDC-0575
- Purity
- 99.50%
- Packaging
- 50mg
- Price
- $1200
- Updated
- 2021/12/16
- Product number
- CS-0043591
- Product name
- GDC-0575
- Purity
- 99.50%
- Packaging
- 100mg
- Price
- $2100
- Updated
- 2021/12/16
(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide Chemical Properties,Usage,Production
Uses
GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC50 of 1.2 nM.
Synthesis
1196508-04-9
1196541-47-5
(0010) To a 1 L inert jacketed reactor equipped with a mechanical stirrer, nitrogen/vacuum manifold, thermocouple, and condenser was added (R)-5-bromo-4-(3-(tert-butoxycarbonylamino)piperidin-1-yl)-3-nitro-1H-pyrrolo[2,3-b]pyridine (1:1 toluene solvent compound) (30.0 g, 1.00 equiv) and tetrahydrofuran ( 180 mL, 6.00 mL/g). Subsequently, 4.5 M piperazine aqueous solution (42.4 g dissolved in 190 mL of water) was slowly added to the reaction mixture while maintaining the temperature at 0 °C. Next, sulfuric acid (36.1 mL, 3.00 eq.) was added and the reaction mixture was stirred at 25 °C for 2 hours. Upon completion of the reaction, 15.0 mL of saturated brine was added and the aqueous phase was separated. The organic phase was stirred for 5 minutes at 20 °C before water (22.0 mL) was added and subjected to continuous distillation at 50 °C. The ethanol feed rate was adjusted to match the distillation rate by adjusting the ethanol feed rate until a total of 260 mL of ethanol was added. Subsequently, water (340 mL) was added over a period of 1 hour at 50 °C. The resulting solid was separated by filtration and washed with 20% aqueous ethanol (2 x 60 mL). Finally, drying in a vacuum oven at 50 °C overnight gave 16.4 g (78% corrected yield) of (R)-5-bromo-4-(3-aminopiperidin-1-yl)-3-(cyclopropanecarboxamido)-1H-pyrrolo[2,3-b]pyridine as a light yellow solid. Note: The 1H NMR and 13C NMR spectra of the free base product have broader signals, so the spectra shown are after conversion of the free base to the bis-HCl salt.1H NMR (300 MHz, DMSO-d6): δ 11.98 (br, 1H), 9.78 (s, 1H), 8.44 (br, 3H), 8.25 (s, 1H), 7.45 (d, J = 2.4 Hz, 1H), 3.57 (m, 1H), 3.43 (m, 1H), 3.41 (m, 1H), 3.28 (m, 1H), 3.14 (m, 1H), 2.15 (m, 1H), 1.90 (penta, J = 6.5 Hz, 1H), 1.81 (m, 1H), 1.72 (m, 1H), 1.52 (m, 1H ), 0.83 (m, 4H).13C NMR (75 MHz, DMSO-d6): δ 172.9, 149.5, 145.9, 145.1, 121.9, 114.2, 113.1, 107.8, 53.8, 51.1, 47.5, 28.6, 24.37, 14.7, 7.55, 7.45.HRMS- ESI (m/z): [M + H]+ calculated value C16H21BrN5O, 378.0924; measured value, 378.0912.
in vivo
GDC-0575 is active at 25 mg/kg as a single agent, but the efficacy is improved at the higher drug dose. GDC-0575 effectively blocks tumor growth in the D20 and C002 xenografts, and the effect is maintained for at least 10 days after the final dose is administered[1].
References
[1] Oo ZY, et al. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Mar 13. doi: 10.1158/1078-0432.CCR-17-2701. DOI:10.1158/1078-0432.CCR-17-2701
[2] Laroche-Clary A, et al. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29(4):1023-1029. DOI:10.1093/annonc/mdy039
[3] Di Tullio A, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8(1):1679. DOI:10.1038/s41467-017-01834-4
(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide Preparation Products And Raw materials
Raw materials
Preparation Products
(R)-N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide Suppliers
- Tel
- 13816613772
- Fax
- QQ: 12922499
- huahero21@sina.com
- Country
- China
- ProdList
- 2391
- Advantage
- 55
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- 400-6206333 13167063860
- Fax
- 021-50323701
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 25003
- Advantage
- 65
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
- Country
- China
- ProdList
- 3506
- Advantage
- 58
- Tel
- 028-81700200 18116577057
- Fax
- 028-81705658
- 3003855609@qq.com
- Country
- China
- ProdList
- 7778
- Advantage
- 56
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4757
- Advantage
- 55
- Tel
- 18800159827
- youcochem@163.com
- Country
- China
- ProdList
- 162
- Advantage
- 50
- Tel
- 021-61350663 13052117465
- Fax
- 021-61350662
- sales@zehanbiopharma.com
- Country
- China
- ProdList
- 984
- Advantage
- 55
- Tel
- 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 9923
- Advantage
- 65
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60